BioNxt Solutions (OTCMKTS:BNXTF) (OTCMKTS:BNXTF) is a biotechnology company that specializes in sustainable, plant cell culture–based production of high-value proteins, biopharmaceuticals and specialty compounds. The company’s core business leverages its proprietary B-CUBE platform to develop consistent, scalable active ingredients for pharmaceutical, cosmetic and nutraceutical applications. By harnessing plant cell culture technology, BioNxt aims to overcome the variability and supply chain constraints associated with traditional agricultural sources.
Through its B-CUBE system, BioNxt Solutions produces a wide array of proteins, enzymes and therapeutic molecules, including growth factors, cytokines and diagnostic reagents, all manufactured under current Good Manufacturing Practices (cGMP). The platform also enables the biosynthesis of rare cannabinoids free from agricultural contaminants, addressing the demands of research institutions and commercial partners for reproducible, high-purity materials.
Founded in 2013 and headquartered in Winnipeg, Canada, BioNxt has expanded its footprint with research and production facilities in Europe and North America. The company has forged strategic collaborations with contract research organizations, academic centers and industry leaders to support regulatory compliance and accelerate commercialization. Its global partnerships facilitate tailored solutions for clients across diverse regulatory environments.
BioNxt Solutions is guided by a multidisciplinary executive team with extensive experience in biotechnology, pharmaceutical development and corporate strategy. This leadership group is focused on advancing the B-CUBE platform, expanding the company’s product pipeline and forging new alliances to deliver cost-effective, environmentally sustainable alternatives to conventional biomanufacturing processes.
